# OnCo record rilvegostomig (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rilvegostomig/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rilvegostomig" ;
  schema:name "Rilvegostomig"@en ;
  schema:description "Rilvegostomig is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer, aimed at PD-1 and TIGIT."@en ;
  schema:url <https://onco.cc/drugs/rilvegostomig/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=Rilvegostomig> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "bispecific antibody" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/tigit/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct06692738/>, <https://onco.cc/trials/nct06564844/>, <https://onco.cc/trials/nct06989112/>, <https://onco.cc/trials/nct06921785/>, <https://onco.cc/trials/nct06357533/>, <https://onco.cc/trials/nct06627647/>, <https://onco.cc/trials/nct05775159/>, <https://onco.cc/trials/nct07098338/>, <https://onco.cc/trials/nct06996782/>, <https://onco.cc/trials/nct05123482/>, <https://onco.cc/trials/nct07115043/>, <https://onco.cc/trials/nct05489211/>, <https://onco.cc/trials/nct07720284/>, <https://onco.cc/trials/nct05702229/>, <https://onco.cc/trials/nct06764875/>, <https://onco.cc/trials/nct06467357/>, <https://onco.cc/trials/nct06109779/>, <https://onco.cc/trials/nct07431281/>, <https://onco.cc/trials/nct07069712/>, <https://onco.cc/trials/nct06868277/>, <https://onco.cc/trials/nct07221253/>, <https://onco.cc/trials/nct04995523/> .